Frequency of Hyperandrogenism in Young Women with Polycystic Ovarian Syndrome: Hyperandrogenism in Young Women with Polycystic Ovarian Syndrome

Rozina  Khatoon; Samreen  Fakeer Muhammad; Uzma  Batool; Rozina Khan; Sadia  Rafiq; Jameela  Bashir Rind

doi:10.54393/pbmj.v5i7.632

Authors

Rozina Khatoon Department of Obstetrics and Gynecology, University Maternity Hospital, Limerick, Ireland
Samreen Fakeer Muhammad Sandeman Provincial Hospital, Quetta
Uzma Batool Department of Gynecology, Punjab Employees Social Security Institution, Lahore, Pakistan
Rozina Khan Department of Gynecology and Obstetrics, Bolan Medical Complex Hospital Quetta, Pakistan
Sadia Rafiq Department of Gynecology and Obstetrics, United Medical and Dental College, Karachi, Pakistan
Jameela Bashir Rind Department of Obstetrics and Gynecology, Dow International Medical College, Ojha Campus Karachi, Pakistan

DOI:

https://doi.org/10.54393/pbmj.v5i7.632

Keywords:

Hyperandrogenism, Testosterone, Sex Hormone Binding Globulin, Free Androgen Index and Polycystic Ovarian Syndrome

Abstract

Polycystic ovary syndrome (PCOS) is the communal disorder of endocrinology in females of reproductive age. Objective: The purpose of the study was to govern the incidence of hyperandrogenism in young females with polycystic ovarian syndrome. Methods: Total 93 women of age 20 to 35 years with any parity and diagnosed patients of PCOS were included. All patients were assessed biochemically. Serum of testosterone and sex hormone binding globulin analysis was done randomly at any phase of menstrual cycle. Participants were followed in OPD. Free androgen index was calculated. Score more than 5 labeled as Hyperandrogenemia. Data were analyzed using SPSS version 21.0. Results: The mean age was 27.22±4.58 years, with range of 15(20–35) years. Age of 46(49.5%) patients was ≤27 years and age of 47(50.5%) patients was >27 years. 41 patients were married and 52 patients were unmarried. The mean parity was 1.41±0.94 with range of 4(0–4). Results of free androgen index score (FAI) showed that overall mean FAI was 7.80±5.82 with range of 32.60(0.80–33.40). Total 60 patients were found with hyperandrogenism. Among these patients the mean age was 26.93±4.68 years. Ages of 32(53.3%) patients were ≤27 years. participants it was observed that 18 patients were nulliparous, 3 patients had 1-2 parity, and 2 patients had parity more than 2. Chi square results for association of hyperandrogenism showed no significant association with age, marital status, and parity with p>0.05. Conclusion: Hyperandrogenism is an important feature of PCOS. It mainly comes from the ovaries of women diagnosed with PCOS. The best indicator of hyperandrogenism is Serum testosterone levels.

References

Pinola P, Puukka K, Piltonen TT, Puurunen J, Vanky E, Sundström-Poromaa I, et al. Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life. Fertility and Sterility. 2017 Mar; 107(3):788-795.e2. doi: 10.1016/j.fertnstert.2016.12.017.

Kim JJ, Kim D, Yim JY, Kang JH, Han KH, Kim SM, et al. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non‐obese non‐alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics. 2017 Jun; 45(11):1403-1412. doi: 10.1111/apt.14058.

Chang RJ, Dumesic DA. Polycystic ovary syndrome and hyperandrogenic states. InYen and Jaffe's reproductive endocrinology. Elsevier. 2019 Jan: 520-55.

Hachul H, Polesel DN, Tock L, Carneiro G, Pereira AZ, Zanella MT, et al. Sleep disorders in polycystic ovary syndrome: influence of obesity and hyperandrogenism. Revista da Associacao Medica Brasileira (1992). 2019 Mar; 65(3):375-383. doi: 10.1590/1806-9282.65.3.375.

Cutler DA, Pride SM, Cheung AP. Low intakes of dietary fiber and magnesium are associated with insulin resistance and hyperandrogenism in polycystic ovary syndrome: A cohort study. Food Science and Nutrition. 2019 Feb; 7(4):1426-1437. doi: 10.1002/fsn3.977.

Kogure GS, Silva RC, Miranda-Furtado CL, Ribeiro VB, Pedroso DC, Melo AS, et al. Hyperandrogenism enhances muscle strength after progressive resistance training, independent of body composition, in women with polycystic ovary syndrome. The Journal of Strength & Conditioning Research. 2018 Sep; 32(9):2642-2651. doi: 10.1519/JSC.0000000000002714.

Pasquali R, Gambineri A. New perspectives on the definition and management of polycystic ovary syndrome. Journal of Endocrinological Investigation. 2018 Oct; 41(10):1123-1135. doi: 10.1007/s40618-018-0832-1.

Copp T, Jansen J, Doust J, Mol BW, Dokras A, McCaffery K. Are expanding disease definitions unnecessarily labelling women with polycystic ovary syndrome? British medical journal BMJ. 2017 Aug; 358: j3694. doi: 10.1136/bmj. j3694.

Amiri M, Tehrani FR, Bidhendi-Yarandi R, Behboudi-Gandevani S, Azizi F, Carmina E. Relationships between biochemical markers of hyperandrogenism and metabolic parameters in women with polycystic ovary syndrome: A systematic review and meta-analysis. Hormone and Metabolic Research. 2019 Jan; 51(1):22-34. doi: 10.1055/a-0806-8281.

Fenichel P, Rougier C, Hieronimus S, Chevalier N. Which origin for polycystic ovaries syndrome: Genetic, environmental or both? Annales d'Endocrinologie (Paris). 2017 Jul; 78(3):176-185. doi: 10.1016/j.ando.2017.04.024.

O'Brien B, Dahiya R, Kimble R. Hyperandrogenism, insulin resistance and acanthosis nigricans (HAIR-AN syndrome): an extreme subphenotype of polycystic ovary syndrome. BMJ Case Reports. 2020 Apr; 13(4): e231749. doi: 10.1136/bcr-2019-231749.

Chan JL, Kar S, Vanky E, Morin-Papunen L, Piltonen T, Puurunen J, et al. Racial and ethnic differences in the prevalence of metabolic syndrome and its components of metabolic syndrome in women with polycystic ovary syndrome: a regional cross-sectional study. American journal of obstetrics and gynecology. 2017 Aug; 217(2): 189.e1-189.e8. doi: 10.1016/j.ajog.2017.04.007.

Saleem F, Rizvi SW. New Therapeutic Approaches in Obesity and Metabolic Syndrome Associated with Polycystic Ovary Syndrome. Cureus. 2017 Nov; 9(11): e1844. doi: 10.7759/cureus.1844.

González F, Considine RV, Abdelhadi OA, Acton AJ. Inflammation Triggered by Saturated Fat Ingestion Is Linked to Insulin Resistance and Hyperandrogenism in Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2020 Jun; 105(6): e2152–67. doi: 10.1210/clinem/dgaa108.

Amiri M, Ramezani Tehrani F, Nahidi F, Bidhendi Yarandi R, Behboudi-Gandevani S, Azizi F. Association between biochemical hyperandrogenism parameters and Ferriman-Gallwey score in patients with polycystic ovary syndrome: A systematic review and meta-regression analysis. Clinical Endocrinology (Oxf). 2017 Sep; 87(3):217-230. doi: 10.1111/cen.13389.

Pasquali R, Pignatelli D, editors. Hyperandrogenism in women: Beyond polycystic ovary syndrome. Karger Medical and Scientific Publishers; 2019 Sep.

Çoban ÖG, Tulacı ÖD, Adanır AS, Önder A. Psychiatric Disorders, Self-Esteem, and Quality of Life in Adolescents with Polycystic Ovary Syndrome. Journal of Pediatric and Adolescent Gynecology 2019 Dec; 32(6):600-604. doi: 10.1016/j.jpag.2019.07.008.

Shengir M, Krishnamurthy S, Ghali P, Deschenes M, Wong P, Chen T, et al. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome. World Journal of Gastroenterology. 2020 Nov; 26(44):7046-7060. doi: 10.3748/wjg. v26.i44.7046.

Al Nofal A, Viers LD, Javed A. Can the source of hyperandrogenism in adolescents with polycystic ovary syndrome predict metabolic phenotype? Gynecological Endocrinology. 2017 Nov; 33(11):882-887. doi: 10.1080/09513590.2017.1342236.

Paixão L, Ramos RB, Lavarda A, Morsh DM, Spritzer PM. Animal models of hyperandrogenism and ovarian morphology changes as features of polycystic ovary syndrome: a systematic review. Reproductive Biology and Endocrinology. 2017 Feb; 15(1):12. doi: 10.1186/s12958-017-0231-z.

Hansen SL, Bojsen-Møller KN, Lundsgaard AM, Hendrich FL, Nilas L, Sjøberg KA. Mechanisms underlying absent training-induced improvement in insulin action in lean, hyperandrogenic women with polycystic ovary syndrome. Diabetes. 2020 Nov; 69(11):2267-2280. doi: 10.2337/db20-0062.

Choudhary A, Jain S, Chaudhari P. Prevalence and symptomatology of polycystic ovarian syndrome in Indian women: is there a rising incidence? International Journal of Reproduction, Contraception, Obstetrics and Gynecology. 2017 Nov; 6(11):4971-6.

Otto-Buczkowska E, Grzyb K, Jainta N. Polycystic ovary syndrome (PCOS) and the accompanying disorders of glucose homeostasis among girls at the time of puberty. Pediatric Endocrinology Diabetes and Metabolism. 2018; 24(1):40-44. doi: 10.18544/PEDM-24.01.0101.

Gupta M, Singh D, Toppo M, Priya A, Sethia S, Gupta P. A cross sectional study of polycystic ovarian syndrome among young women in Bhopal, Central India. The International Journal of Community Medicine and Public Health 2018 Jan; 5(1):95-100.

Sørensen AE, Udesen PB, Maciag G, Geiger J, Saliani N, Januszewski AS, et al. Hyperandrogenism and metabolic syndrome are associated with changes in serum-derived microRNAs in women with polycystic ovary syndrome. Frontiers in medicine (Lausanne). 2019 Nov; 6:242. doi: 10.3389/fmed.2019.00242.